Myriad Genetics

$18.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.45 (-2.41%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell MYGN and other stocks, options, and ETFs commission-free!

About MYGN

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT. The listed name for MYGN is Myriad Genetics, Inc. Common Stock.

CEO
Paul J. Diaz
Employees
2,700
Headquarters
Salt Lake City, Utah
Founded
1991
Market Cap
1.37B
Price-Earnings Ratio
Dividend Yield
Average Volume
802.53K
High Today
$18.64
Low Today
$17.71
Open Price
$18.44
Volume
514.60K
52 Week High
$30.13
52 Week Low
$9.24

Collections

MYGN Earnings

-$0.47
-$0.16
$0.16
$0.47
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
per share
Actual
Expected Feb 4, Pre-Market

You May Also Like